Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine, the standard antidote for AMD, currently has very limited availability in the United States due to an interruption of production.
Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD, but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care. In order to investigate the effectiveness of rivastigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo.

Start Date01 Nov 2026

Sponsor / Collaborator

Washington University School of Medicine

[+1]

IRCT20250611066174N2

/ SuspendedPhase 3IIT

Evaluation of the effectiveness of rivastigmine in improving negative symptoms in chronic psychotic patients

Start Date21 Sep 2025

Sponsor / Collaborator

Zahedan University of Medical Sciences

NCT07208344

/ RecruitingEarly Phase 1IIT

A Randomized Double-blind Clinical Study on the Use of Umbilical Cord Blood as an Adjuvant Therapy to Improve Cognitive Function in Alzheimer's Disease and Its Mechanism of Action

This study is a single-center, prospective, double-blind, randomized controlled clinical trial (RCT).
Employing a parallel-group design, the trial plans to enroll 30 clinically diagnosed AD patients, who will be randomly assigned via a computerized randomization tool into three equal groups: low-dose, high-dose, and control (10 patients per group).
The blinded clinical trial consists of three phases:
**Screening Phase**: All enrolled patients must provide fully informed consent and meet inclusion criteria while avoiding exclusion criteria. Baseline assessments will be recorded, and single-cell omics samples will be collected. Patients may voluntarily opt for cerebrospinal fluid (CSF) sampling.
The umbilical cord blood (UCB) used clinically is sourced from the Shandong Cord Blood Hematopoietic Stem Cell Bank. Following erythrocyte and granulocyte depletion via lymphocyte separation and density gradient centrifugation, the UCB is purified to reduce immunogenicity and undergoes genetic screening to exclude the APOE4 risk allele.
**Treatment Phase**: In addition to standard care, patients will receive intravenous infusions at weekly intervals for four sessions. A fifth infusion will be administered one month after the fourth. The low-dose group receives 1×10⁸ UCB-derived mononuclear cells (UCB-MNCs) per infusion, the high-dose group receives 3×10⁸ UCB-MNCs, and the control group receives an equivalent volume of saline placebo.
All clinically administered UCB-MNCs undergo genetic screening to exclude the APOE4 risk allele.
**Follow-up Phase**:
Assessments will be conducted at 30 days (1 month), 60 days (2 months), 90 days (3 months), and 180 days (6 months) post-initial infusion, including:
1. CDR-SB scale scoring;
2. Total and subdomain scores of the Activities of Daily Living (ADL) scale;
3. Serum inflammatory cytokines (IL-1, IL-2, IL-6, IL-8, IL-10, TNF-α), AD biomarkers (P-tau181, P-tau217), and other relevant markers;
4. Single-cell omics sample collection;
5. Optional CSF sampling per patient preference.
After database lock, unblinding will occur for subsequent analysis.

Start Date31 Jul 2025

Sponsor / Collaborator

Anhui Provincial Hospital

[+1]

100 Clinical Results associated with Rivastigmine Tartrate

100 Translational Medicine associated with Rivastigmine Tartrate

100 Patents (Medical) associated with Rivastigmine Tartrate

2,763

Literatures (Medical) associated with Rivastigmine Tartrate

01 Apr 2026·ARCHIVES OF MICROBIOLOGY

Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria

Article

Author: Tripathi, Renu ; Joshi, Prince ; Sharma, Anamika ; Shaham, Salique Hassan ; Shivahare, Rahul ; Shukla, Shubha ; Yadav, Kanchan ; Parul

Cerebral malaria (CM) remains one of the most severe complications of Plasmodium falciparum infection, often leading to death within days and leaving survivors with lasting cognitive damage. Since current treatments target the parasite but offer little to no neuroprotection, we explored whether existing neuroprotective drugs could help fill this gap. Six clinically-approved drugs, viz. topiramate, rasagiline, vinpocetine, cilostazol, piracetam, and rivastigmine were tested for both antimalarial and anti-cerebral malaria activity. Screening against P. falciparum in vitro showed that vinpocetine, cilostazol, and rivastigmine effectively inhibited parasite growth, without causing toxicity in Vero or BB19 cell lines or in human red blood cells. In a mouse model of experimental CM (Plasmodium berghei ANKA-infected C57BL/6 mice), early oral treatment with cilostazol, piracetam, or rivastigmine delayed the onset of CM symptoms and significantly improved survival compared to untreated controls. When treatment was initiated after the first neurological signs, only the combination of rivastigmine with the fast-acting antimalarial α/β-arteether markedly improved outcomes, including parasite clearance and extended survival, compared to either treatment alone. Overall, these results suggest that combining rivastigmine with α/β-arteether may represent a practical and low-cost adjunct therapy for CM. Further mechanistic and clinical studies will be essential to confirm these findings and assess long-term outcomes.

01 Feb 2026·BEHAVIOURAL PHARMACOLOGY

Effects of hydromethylthionine mesylate and rivastigmine in a pharmacological mouse model of Alzheimer’s disease

Article

Author: Melis, Valeria ; Harrington, Charles R. ; Bray, Jack ; Riedel, Gernot ; Wischik, Claude M. ; Robinson, Lianne

The results from clinical trials have indicated that the tau aggregation inhibitor hydromethylthionine mesylate (HMTM) produces disease-modifying effects in Alzheimer’s disease (AD) patients when administered alone, but less of an effect when administered in conjunction with cholinesterase inhibitors (ChEIs). The use of ChEIs for AD has been supported by their ability to reverse scopolamine-induced cognitive impairments in rodents reminiscent of those seen in AD patients. We have previously shown that another tau aggregation inhibitor, methylthionine chloride (MTC), is able to reverse scopolamine-induced deficits in spatial learning and memory. The objective here was to determine the symptomatic efficacy of HMTM and rivastigmine, alone or in combination, in a scopolamine model of AD. Female NMRI mice were treated systemically with scopolamine (0.5 mg/kg) or vehicle in combination with ChEI rivastigmine (0.5 mg/kg) or HMTM (5 or 15 mg/kg) daily before assessment of spatial learning and memory performance in a reference memory task in the water maze. Systemic administration of scopolamine induced significant impairments in the spatial learning of the mice compared to vehicle treatment. These deficits were reversed by treatment with HMTM at both doses and with rivastigmine when given alone. Furthermore, coadministration of rivastigmine with HMTM ameliorated the impairments induced by scopolamine. These findings extend our previous observations with MTC and confirm that HMTM also has a dual mode of action, disease modification through tau aggregation inhibition, but also having symptomatic effects through its normalisation of cholinergic activity.

01 Feb 2026·TALANTA

Development of sustainable N,S carbon quantum dots turn-off fluorescence method for rivastigmine determination using box-behnken design in pharmaceutical and environmental applications

Article

Author: Alzhrani, Rami M ; Almalki, Atiah H ; Abduljabbar, Maram H ; Alnemari, Reem M ; Serag, Ahmed

Rivastigmine, a dual cholinesterase inhibitor used for dementia treatment, poses significant environmental concerns due to its persistence in aquatic systems and potential ecotoxicological effects on non-target organisms, necessitating sensitive analytical methods for environmental monitoring. Herein, a novel, sensitive, and environmentally sustainable spectrofluorimetric method was developed for rivastigmine determination using nitrogen and sulfur co-doped carbon quantum dots (N,S CQDs) as fluorescence probes. The N,S CQDs were synthesized via a rapid microwave-assisted carbonization method and subsequently characterized using different techniques to elucidate their morphological, structural, and optical properties. The fluorescence quenching mechanism was then systematically investigated through Stern-Volmer kinetic analysis at three temperatures (298-313 K) revealing inverse temperature dependence of quenching constants Ksv (5.57 × 10⁵ to 3.86 × 10⁵ M^-1), thereby confirming static quenching through ground-state complex formation. Additionally, thermodynamic analysis revealed exothermic binding (ΔH = -21.06 kJ/mol) with spontaneous complex formation. Subsequently, critical analytical parameters including pH, N,S CQDs volume, and reaction time were systematically optimized using Box-Behnken experimental design. Notably, response surface methodology revealed significant factors such as pH and N,S CQDs volume as well as synergistic interactions between these factors, which yielded a predictive mathematical model (R² = 0.9759) with optimized conditions: pH 6.0, N,S CQDs volume 0.9 mL, and reaction time 3 min. The method was validated according to the ICH guidelines demonstrating high analytical performance with linear range 0.05-1.5 μg/mL (r² = 0.9996), low detection limit (0.0165 μg/mL), high accuracy (98.92 ± 1.207 %), and good precision (RSD <2 %). The method was then successfully applied to pharmaceutical formulations and environmental water samples with satisfactory recovery rates (95.43-103.26 %). Comprehensive greenness and blueness assessments using AGREE and BAGI tools revealed superior environmental performance (0.77) compared to conventional HPLC-UV methods (0.63) while maintaining acceptable practical applicability (77.5). The developed method offers a viable green alternative for rivastigmine determination in pharmaceutical and environmental analysis.

News (Medical) associated with Rivastigmine Tartrate

25 Feb 2026

·www.businesswire.com

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting. The BEACON study is designed to assess the real-world impact of ZUNVEYL on cognition, neuropsychiatric symptoms, safety, and tolerability in patients with Alzheimer’s disease residing in nursing homes. By generating data in routine clinical practice, the study aims to complement findings from earlier clinical trials and provide practice-relevant evidence in a care setting with significant unmet need that will further support the Company’s commercialization efforts. “Enrollment of first patient in the BEACON study represents a significant milestone for Alpha Cognition,” said Kurt Grady, Alpha Cognition’s Vice President of Medical Affairs. “This study is designed to generate real-world clinical evidence in the nursing home environment, where the need for effective and well-tolerated therapies is particularly high. If positive, these data have the potential to further strengthen the clinical foundation for ZUNVEYL and support our ongoing commercial launch by providing meaningful insights for healthcare providers, patients, and caregivers.” BEACON is a post-approval study expected to enroll approximately 200 patients across multiple clinical sites. The study will collect efficacy data and monitor adverse events throughout the study period, contributing to ongoing post-market evaluation and informing real-world clinical use of ZUNVEYL in the long-term care population. Alpha Cognition expects to report topline results in the fourth quarter of 2026, following completion of enrollment and patient follow-up. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements with the anticipated results of the BEACON study and the potential for such results to further strengthen the clinical foundation for ZUNVEYL and support its ongoing commercial launch, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on May 31, 2025 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

Phase 2Phase 3

18 Feb 2026

·www.alphacognition.com

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL® Dosing Regimens

VANCOUVER, B.C. and GRAPEVINE, TX — February 18, 2026 — Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled “Dosage Regimens for Benzgalantamine.” The issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer’s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company’s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition’s FDA-approved therapy for mild to moderate Alzheimer’s disease. “This newly issued patent meaningfully strengthens the intellectual property protection surrounding ZUNVEYL by covering clinically relevant dosing regimens for oral administration,” said Michael McFadden, Chief Executive Officer of Alpha Cognition. “These method-of-use claims extend and reinforce our existing patent portfolio, supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value in the U.S. market.” The issuance of this patent further advances Alpha Cognition’s long-term intellectual property strategy by protecting key methods of administering benzgalantamine and extending exclusivity beyond existing patent coverage. The Company believes this patent underscores the innovative nature of its benzgalantamine research and supports durable market protection for ZUNVEYL. About Alpha Cognition Inc. Alpha Cognition Inc. is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s expectation that the additional U.S. patent will provide U.S. patent protection through July 2045 and supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value and protecting key methods of administering benzgalantamine, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2025 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. For further information: Investor Relations LifeSci Advisors, PJ Kelleher pkelleher@lifesciadvisors.com

Drug ApprovalPatent Expiration

18 Feb 2026

·www.biospace.com

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled “Dosage Regimens for Benzgalantamine.” The issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer’s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company’s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition’s FDA-approved therapy for mild to moderate Alzheimer’s disease. “This newly issued patent meaningfully strengthens the intellectual property protection surrounding ZUNVEYL by covering clinically relevant dosing regimens for oral administration,” said Michael McFadden, Chief Executive Officer of Alpha Cognition. “These method-of-use claims extend and reinforce our existing patent portfolio, supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value in the U.S. market.” The issuance of this patent further advances Alpha Cognition’s long-term intellectual property strategy by protecting key methods of administering benzgalantamine and extending exclusivity beyond existing patent coverage. The Company believes this patent underscores the innovative nature of its benzgalantamine research and supports durable market protection for ZUNVEYL. About Alpha Cognition Inc. Alpha Cognition Inc. is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s expectation that the additional U.S. patent will provide U.S. patent protection through July 2045 and supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value and protecting key methods of administering benzgalantamine, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2025 and available at . These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. Contacts Investor Relations LifeSci Advisors, PJ Kelleher pkelleher@lifesciadvisors.com

Drug ApprovalPatent Expiration

100 Deals associated with Rivastigmine Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02558	Rivastigmine Tartrate	N06DA03	DB00989

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Progressive Supranuclear Palsy Atypical	United States	Sandoz, Inc.	06 Jul 2007
Parkinson Disease	United States	Novartis Pharmaceuticals Corp.	27 Jun 2006
Alzheimer Disease	United States	Novartis Pharmaceuticals Corp.	21 Apr 2000
Dementia	United States	Novartis Pharmaceuticals Corp.	21 Apr 2000
Dementia due to Alzheimer's disease (disorder)	European Union	Novartis Europharm Ltd.	11 May 1998
Dementia due to Alzheimer's disease (disorder)	Iceland	Novartis Europharm Ltd.	11 May 1998
Dementia due to Alzheimer's disease (disorder)	Liechtenstein	Novartis Europharm Ltd.	11 May 1998
Dementia due to Alzheimer's disease (disorder)	Norway	Novartis Europharm Ltd.	11 May 1998
Dementia due to Parkinson's disease	European Union	Novartis Europharm Ltd.	11 May 1998
Dementia due to Parkinson's disease	Iceland	Novartis Europharm Ltd.	11 May 1998
Dementia due to Parkinson's disease	Liechtenstein	Novartis Europharm Ltd.	11 May 1998
Dementia due to Parkinson's disease	Norway	Novartis Europharm Ltd.	11 May 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Delirium	Phase 3	France	Novartis Pharmaceuticals Corp.	01 Jun 2011
Emergence Delirium	Phase 3	Switzerland	Novartis AG	01 Jan 2006
Neurobehavioral Manifestations	Phase 3	-	Novartis AG	01 Jan 2003
Brain Injuries, Traumatic	Phase 3	-	Novartis AG	01 Nov 2002
Cognitive Dysfunction	Phase 3	-	Novartis AG	01 Nov 2002
Dementia, Vascular	Phase 3	United States	Novartis Pharmaceuticals Canada, Inc.	01 Aug 2001
Dementia, Vascular	Phase 3	Austria	Novartis Pharmaceuticals Canada, Inc.	01 Aug 2001
Dementia, Vascular	Phase 3	Canada	Novartis Pharmaceuticals Canada, Inc.	01 Aug 2001
Dementia, Vascular	Phase 3	France	Novartis Pharmaceuticals Canada, Inc.	01 Aug 2001
Dementia, Vascular	Phase 3	Germany	Novartis Pharmaceuticals Canada, Inc.	01 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02989402 (CTgov)	Phase 4	Dementia due to Alzheimer's disease (disorder)	100	Rivastigmine	sxzvmjznit = tuhppcthin hvehnypmlc (lnnmazlawm, lsuooibgmq - jxvggdbzli) View more	-	31 May 2024
NCT03915626 (CTgov)	Early Phase 1	-	7	Rivastigmine (RLD Patch)	frxsotcfys(abxzeixzep) = twubywedvg mpewcxmqcb (nxzyhszocn, 14.35) View more	-	07 Mar 2022
				Rivastigmine (generic) transdermal patch (Generic Patch)	frxsotcfys(abxzeixzep) = jiejnoxeqj mpewcxmqcb (nxzyhszocn, 11.41) View more
NCT01340885 (CTgov)	Phase 4	Cognitive Dysfunction \| Parkinson Disease	9	Strattera (Atomoxetine)	sjszktyfyy(tcugtchujn) = ohtweavxkc kladhrixhu (rkupilxmis, zafxlgcpcn - agohtddgly) View more	-	07 Jul 2020
				Exelon (Rivastigimine)	sjszktyfyy(tcugtchujn) = hrljjgjkny kladhrixhu (rkupilxmis, jsroibrgnp - cykmqwntjw) View more
NCT02703636 (ENA1stepswitch, CTgov)	Phase 4	Alzheimer Disease \| Dementia due to Alzheimer's disease (disorder)	118	Rivastigmine Patch	rylrunfnfw(oovmjrwahv) = liwhlrgbwh eolfuzzchd (bjjnzibnhz, 3.80) View more	-	12 Sep 2019
NCT02703636 (ENA1stepswitch, Pubmed) Manual	Phase 4	Alzheimer Disease	102	Rivastigmine	fwicymhpol(sxgvajjtnv) = a least-square mean change (SD) of -0.35 (2.64) itzkxglhwn (qvnirlcbjq )	Positive	15 Aug 2019
NCT01380288 (Pubmed \| J Biol Chem \| PLoS One) Manual	Not Applicable	Alzheimer Disease \| Leukoencephalopathies	300	rivastigmine (with minimal WMHs)	fiiyzobrae(tnqttslzxd) = fnvtssrvek cyanqgnxls (aihswnnsfx, 5.70) View more	Positive	07 Aug 2017
				rivastigmine (with moderate WMHs)	fiiyzobrae(tnqttslzxd) = tskrmouukq cyanqgnxls (aihswnnsfx, 5.98) View more
NCT01670526 (RIVET, CTgov)	Phase 3	Cognitive Dysfunction \| Brain Injuries, Traumatic	94	Rivastigmine Transdermal Patch (Rivastigmine)	etddtfbyva = sqesfgibux ymlgfofxfj (kgzmtwdpvi, hwikofdnqr - ywpzabwxws) View more	-	25 Jul 2017
				Rivastigmine Transdermal Patch (Placebo)	etddtfbyva = zmsbozwczq ymlgfofxfj (kgzmtwdpvi, vurqcsdwnf - ldmejdqvqw) View more
NCT01519271 (CTgov)	Phase 4	Mild cognitive disorder \| Parkinson Disease	28	Placebo Patches (Placebo Patch)	pdieuhjdmv(dnaldxwund) = lchzvitvcp whuqcfbxve (soqzzdypcr, 0.94) View more	-	07 Apr 2017
				rivastigmine (Exelon Patch (Rivastigmine Transdermal System))	pdieuhjdmv(dnaldxwund) = gwlhlbzdhm whuqcfbxve (soqzzdypcr, 0.89) View more
NCT01602198 (CTgov)	Not Applicable	Mild cognitive disorder	1	Exelon [rivastigmine] transdermal patch (Exelon Transdermal Patch)	xelhuuaxpe(fqkwyjaoii) = hxujanenfx ibzvcxqwam (xmnbkddhqi, ompnrkbyiw - uowhgnzoqs) View more	-	28 Feb 2017
				Placebo transdermal patch (Placebo Transdermal Patch)	xelhuuaxpe(fqkwyjaoii) = evgjkrhfte ibzvcxqwam (xmnbkddhqi, toxrsisoht - muqcwyvscc) View more
NCT01362686 (COMET-AD, CTgov)	Not Applicable	Alzheimer Disease	200	Donepezil (Donepezil)	bzrrtcjljl = wsfzdlpzgq menqxnpozz (ounabnwajo, ynfdnjxjzi - rhdjcbmpwy) View more	-	27 Feb 2017
				Galantamine (Galantamine)	bzrrtcjljl = suxqnnmybn menqxnpozz (ounabnwajo, hbebinhezg - czpjtbdwrp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis